person
Mohamad M.
- Country
- France
- Department
- N/A
Research Overview
assignment
36
Clinical Trials ·
- TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma
- Phase I Study of OT-A201 in Patients with Relapsed/Refractory Hematological Malignancies or Advanced/Metastatic Solid Tumors
- Dose Optimization and Safety Evaluation of ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma
location_city
6
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
272
Sites with multiple studies
Has run more than one trial at 272 of 427 partner sites.
Specializations
Multiple Myeloma Management
The investigator specializes in treating multiple myeloma across various disease stages, with particular focus on innovative therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- Newly Diagnosed Multiple Myeloma Treatment
- Relapsed/Refractory Multiple Myeloma Interventions
- Transplant-Eligible and Ineligible Patient Care
Novel Therapeutic Approaches
Focuses on implementing cutting-edge treatments including bispecific antibodies and cellular therapies for hematologic malignancies.
- Immunotherapy Applications
- Targeted Therapeutic Combinations
- Minimal Residual Disease Assessment
Stem Cell Transplantation
Expertise in autologous stem cell transplantation procedures and their integration with modern therapeutic strategies.
- Transplant Conditioning Protocols
- Post-Transplant Maintenance Therapy
- Treatment Response Evaluation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.